Commercial Expertise: We provide expert advice on the commercialisation of biotech and MedTech innovations, beyond the Regulatory Clearances, i.e. Health Economics, Reimbursement, Distribution and most importantly Adoption. Med2Mark thoroughly assesses the commercial
value of Health-Tech innovations before significant investments are committed. We are selective and engage, for the long run, in projects with strong commercialisation and actual adoption potentials.
Global Experience: We are an international boutique Consulting Practice with over twenty years’ experience in the commercialisation of Biotech and Medtech innovations in the USA, Europe and Australia. We are available to directly support the management team, as illustrated
by David’s Executive positions in Philia Labs, Attilio’s CEO position in Verum Diagnostics, as well as Pierre’s CEO position in Jay-Nik, three startups we came across through our consulting activities.
Definition of Health Impact Strategies: Assessment of the heathcare system’s capacity to maximise the potential benefits of your innovation at the delivery point.
Substantiation of Health Economics value to build Reimbursement dossiers: Clinical and economic...
Market Access Strategy: We map out the regulatory pathways and reimbursement options applicable to your innovation.
Markets Assessment & Financial Modelling: From the Global Market to the Total Addressable Market, we provide you with actionable information...
KOLs Engagement & early adoption: Engagement of subject experts and Key Opinion Leaders to accelerate early adoption of your innovation.
Validate the financial projections to support fundraising activities and exit negotiations.
Advice to Investors based on expected commercial returns: We translate the complexities of healthtech commercialisation into a succinct dashboard...
Created in 2017, Med2Mark is a boutique Consulting Practice built around seven Associates, each with over twenty years’ experience in the translation of Biotech and Medtech innovations. Our clients are located in the USA, Europe, China and Australia.
Together, in the last 2 years, we have helped bring 2 BioTech, 1 MedTech and 6 IVD products to the market.
Across the USA, Europe, Asia and Australia.
Experience in Biotech & Medtech.
Our Client: US-based Biotech start-up commercialising a range of patented natural source products for the oral health and anti-viral consumer and therapeutics market.
What we did: Researched and detailed the overall value of the proposed program and its expected outcomes with an accompanying market opportunity analysis, summary finance plan, and market channel approaches.
Our results: Phase II grant successfully funded with a high score for the commercial strategy section.
Our Client: Australia-based MedTech start-up.
What we did: Strategic analysis of the market (Porter) resulting in recommendation to consolidate IP and exit early.
Our results: Recommendation accepted and backed up by private investors.
Our Client: Singapore-based BioTech start-up commercialising 3D cell-based test that mimics patients’ response to cytostatic drugs.
What we did: A comprehensive Health Technology Assessment centred on Health Economics evidence (ICER).
Our results: Test reimbursed by the two targeted German private health insurance companies.
Our Client: US-based contract manufacturer of lateral flow devices.
What we did: Process map, draft SOPs, WIs, Forms and Templates, guide.
Our results: Achieved certification to ISO 13485 within 8 months.
We help you turn your health-tech innovations into commercial successes.